Study finds new dual benefit mode of action for drug candid...| MENAFN.COM

Friday, 21 January 2022 08:41 GMT

Study finds new dual benefit mode of action for drug candidate to fight Covid


(MENAFN- IANS)

London, Jan 15 (IANS) A team of researchers has found a new dual attack mode of action while working on the development of a drug candidate against SARS-CoV-2 infections.

According to the study, published in the journal Cellular and Molecular Life Sciences, this could constitute the basis for a broadly effective drug to fight Covid-19.

The drug can not only inhibit the proliferation of SARS-CoV-2 viruses in cells, but also reduce the exaggerated immune response which represents a serious problem in severe cases of Covid-19.

'In the results, we have published, we have been able for the first time to show such a dual action for an anti-Covid 19 agent,' said researcher Stephan Ludwig from the University of Munster.

The active agent in question, called Zapnometinib or ATR-002, which was originally under development as anti-flu medication, was effective in a variety of cell culture models -- including activity against all tested variants of SARS-CoV-2, which also implies broad applicability in facing up to any coming variants in the future.

Animal testing to confirm these findings are currently under-way, the team said.

'Positive results from the still ongoing clinical study in humans might already lead to an emergency approval this year for a new, broadly effective Covid-19 medication. The benefit is clear,' said Ludwig.

--IANS

vc/shb/

MENAFN15012022000231011071ID1103543075


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.